Innovation Pharmaceuticals Inc (IPIX)

[williamssc]

This from the George Mason university attachment (conclusion) is huge in the aspect that there is now a nasal form of B being tested tweaked for in vivo effectiveness in other words in the body of a living organism.

"Brilacidin is thus able to exert a combined protective effect by decreasing both viral and inflammatory load. Brilacidin has undergone several clinical studies as treatment for bacterial infections. Ongoing efforts are focused on dosing strategies for brilacidin to improve in vivo effectiveness in the form of a nasally-delivered countermeasure.

https://static1.squarespace.com/static/5715352e20c647639137f992/t/63226423ad15bb3c77223340/1663198243904/MHSRS2022+-+Brilacidin+poster+fv.pdf